ALT Ishares Diversified Alternatives Trust

Alteon To Present at The BIO CEO & Investor Conference 2005 - Presentation to be Webcast - PARSIPPANY, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that Kenneth I. Moch, President & Chief Executive Officer, will present at the BIO CEO & Investor Conference, Wednesday, February 23, 2005, 3:30 pm, ET, at The Waldorf-Astoria, New York, NY. Mr. Moch will discuss the clinical objectives for the ongoing Phase 2 programs of alagebrium in systolic hypertension, heart failure and erectile dysfunction, as well as provide an update of 2005 milestones. The presentation will be webcast and can be viewed at the investor relations section of Alteon's website, http://www.alteon.com/. It will be archived there after the event. Note to BIO attendees: Alteon will be available for one-on-one meetings. Please arrange through BIO or by calling Susan Pietropaolo at 201-818-5537. About Alteon Alteon is developing several new classes of drugs that have shown the potential to reverse or slow down diseases of aging and complications of diabetes. These compounds appear to have an impact on a fundamental pathological process caused by the progressive formation of protein-glucose complexes called Advanced Glycation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss of flexibility and function in body tissues and organs and have been shown to be a causative factor in many age- related diseases and diabetic complications. Alteon has created a library of novel classes of compounds targeting the A.G.E. pathway. Alteon's lead compound alagebrium chloride (formerly ALT-711), the only A.G.E. Crosslink Breaker in advanced human testing, has demonstrated safety and efficacy in several Phase 2 trials and is actively being developed for systolic hypertension, heart failure and erectile dysfunction. Over 1200 patients have been involved in alagebrium's human clinical trials to date, of whom approximately 900 have received active compound. Ongoing clinical trials include the Phase 2b systolic hypertension trial, SPECTRA (Systolic Pressure Efficacy and Safety Trial of Alagebrium), the Phase 2a heart failure trial, PEDESTAL (Patients with Impaired Ejection Fraction and Diastolic Dysfunction: Efficacy and Safety Trial of ALagebrium), the Phase 2a trial EMERALD (Evaluation of Alagebrium in Erectile Dysfunction in Diabetic Males on PDE5 Inhibitors), as well as a fourth trial exploring mechanism of action in endothelial dysfunction. For more detailed information about alagebrium, please visit the scientific publications section of the Alteon website, http://www.alteon.com/. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development (including the possibility that early clinical trial results may not be predictive of results that will be obtained in large-scale testing or that any clinical trials will not demonstrate sufficient safety and efficacy to obtain requisite approvals or will not result in marketable products), regulatory approval processes, intellectual property rights and litigation, competitive products, ability to obtain financing, and other risks identified in Alteon's filings with the Securities and Exchange Commission. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Alteon undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M. Pietropaolo, Director, Corporate Communications & Investor Relations, +1-201-818-5537, Web site: http://www.alteonpharma.com/

Copyright